TP53 and cancer: In addition to the above arguments, the rationale for usingCCND1, PI3K-H1047R, MYC, TERT, BMI1 andsh-p53 was based on genomic data in luminalbreast cancer and on past experience with mammary transformation protocols.According to the TCGA consortium, PIK3CAmutations are seen in 45% of luminal A and 29% of luminal B tumors; TP53 mutations are seen in 29% of luminal B tumors[35].